Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michael S. Weiss
Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Taste Responses in the Nucleus of the Solitary Tract of Awake Obese Rats Are Blunted Compared With Those in Lean Rats
Frontiers in Integrative Neuroscience
Molecular Neuroscience
Sensory Systems
Cellular
Cognitive Neuroscience
Related publications
Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Tolerability of AZD5363 in Japanese Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase I Study to Assess the Safety and Tolerability of Olaparib in Combination With Bevacizumab in Patients With Advanced Solid Tumours
British Journal of Cancer
Cancer Research
Oncology
Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma
Community Oncology